Novartis | NVS - Cash And Equivalent

Stock Price
152.91
Daily Change
3.12 2.08%
Monthly
10.91%
Yearly
39.25%
Q1 Forecast
145.07

Novartis reported $9.56B in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.63B 838M Sep/2025
Amgen USD 9.13B 316M Dec/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Bausch Health Companies USD 1.31B 419M Sep/2025
Biogen USD 3.86B 1.1B Sep/2025
Bristol-Myers Squibb USD 15.73B 3.13B Sep/2025
Canopy Growth CAD 298.06M 171.86M Sep/2025
Corcept Therapeutics USD 125.14M 22.39M Sep/2025
Drreddys Laboratories INR 18.66B 9.65B Dec/2025
Eli Lilly USD 9.79B 6.42B Sep/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Glaxosmithkline GBP 3.3B 303M Sep/2025
J&J USD 18.23B 10.35B Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Pacira USD 147.59M 152.89M Sep/2025
Perrigo USD 432.1M 22.1M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Prestige Brands USD 119.11M 20.4M Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Supernus Pharmaceuticals USD 151.37M 6.66M Sep/2025
Zoetis USD 2.08B 649M Sep/2025